MA39018A1 - (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse - Google Patents
(aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyseInfo
- Publication number
- MA39018A1 MA39018A1 MA39018A MA39018A MA39018A1 MA 39018 A1 MA39018 A1 MA 39018A1 MA 39018 A MA39018 A MA 39018A MA 39018 A MA39018 A MA 39018A MA 39018 A1 MA39018 A1 MA 39018A1
- Authority
- MA
- Morocco
- Prior art keywords
- bleeding
- pyridopyrazolopyrimidinones
- indazolopyrimidinones
- aza
- prophylaxis
- Prior art date
Links
- ZPUDLYRGRCCCIL-UHFFFAOYSA-N pyrazolo[4,3-f]quinazolin-1-one Chemical class N1=CN=CC2=C3C(=O)N=NC3=CC=C21 ZPUDLYRGRCCCIL-UHFFFAOYSA-N 0.000 title abstract 2
- 230000020764 fibrinolysis Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 208000032843 Hemorrhage Diseases 0.000 abstract 3
- 208000034158 bleeding Diseases 0.000 abstract 3
- 230000000740 bleeding effect Effects 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000001356 surgical procedure Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 201000007120 C1 inhibitor deficiency Diseases 0.000 abstract 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 abstract 1
- 208000018525 Postpartum Hemorrhage Diseases 0.000 abstract 1
- 206010049771 Shock haemorrhagic Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000001780 epistaxis Diseases 0.000 abstract 1
- 208000002085 hemarthrosis Diseases 0.000 abstract 1
- 208000031169 hemorrhagic disease Diseases 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 230000003902 lesion Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 201000004595 synovitis Diseases 0.000 abstract 1
- 238000002054 transplantation Methods 0.000 abstract 1
- 230000008733 trauma Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne de nouvelles (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones substituées, des procédés pour leur préparation, les composés étant destinés à être utilisés seuls ou en association dans une méthode pour le traitement et/ou la prophylaxie de maladies, en particulier pour le traitement et/ou la prophylaxie d'un saignement court et récurrent chez des patients présentant ou non des troubles hémorragiques héréditaires ou acquis sous-jacents, le saignement étant associé à une maladie ou à une intervention chirurgicale choisie dans le groupe constitué par une ménorragie, une hémorragie postpartum, un choc hémorragique, un traumatisme, une chirurgie, une greffe, un accident vasculaire cérébral, des maladies hépatiques, un œdème de quincke héréditaire, un saignement de nez, et une synovite et des lésions cartilagineuses à la suite d'une hémarthrose.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13191642 | 2013-11-05 | ||
| PCT/EP2014/073529 WO2015067549A1 (fr) | 2013-11-05 | 2014-11-03 | (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA39018A1 true MA39018A1 (fr) | 2017-06-30 |
Family
ID=49517406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA39018A MA39018A1 (fr) | 2013-11-05 | 2014-11-03 | (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US9598417B2 (fr) |
| EP (1) | EP3066100B1 (fr) |
| JP (1) | JP6431061B2 (fr) |
| KR (1) | KR102312780B1 (fr) |
| CN (1) | CN105683194B (fr) |
| AP (1) | AP2016009175A0 (fr) |
| AR (1) | AR098292A1 (fr) |
| AU (1) | AU2014345771B2 (fr) |
| CA (1) | CA2929378C (fr) |
| CL (1) | CL2016001076A1 (fr) |
| CR (1) | CR20160332A (fr) |
| CU (1) | CU24361B1 (fr) |
| DO (1) | DOP2016000102A (fr) |
| EA (1) | EA029373B1 (fr) |
| ES (1) | ES2732305T3 (fr) |
| GT (1) | GT201600084A (fr) |
| IL (1) | IL244645B (fr) |
| MA (1) | MA39018A1 (fr) |
| MX (1) | MX370419B (fr) |
| PE (1) | PE20160934A1 (fr) |
| PH (1) | PH12016500828A1 (fr) |
| SG (1) | SG11201602133RA (fr) |
| TN (1) | TN2016000161A1 (fr) |
| TW (1) | TWI657089B (fr) |
| UA (1) | UA117504C2 (fr) |
| UY (1) | UY35809A (fr) |
| WO (1) | WO2015067549A1 (fr) |
| ZA (1) | ZA201602311B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| PE20170920A1 (es) * | 2014-11-03 | 2017-07-12 | Bayer Pharma AG | Piperidinilpirazolopirimidinonas y utilizacion de las mismas |
| WO2016173948A1 (fr) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones comme inhibiteurs de la fibrinolyse |
| WO2017007917A1 (fr) * | 2015-07-07 | 2017-01-12 | Mast Therapeutics, Inc. | Copolymères de polyoxyéthylène/polyoxypropylène et inhibiteurs fibrinolytiques, leurs utilisations et compositions |
| EP3318563A1 (fr) | 2016-11-07 | 2018-05-09 | Sanofi | Pyrido[3,4-b]indoles substitués pour le traitement de troubles du cartilage |
| CN110590673A (zh) * | 2019-09-02 | 2019-12-20 | 南通大学 | 一种4-氯-7-甲基-1h-吲唑及其化学合成方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11654057B2 (en) | 2020-04-09 | 2023-05-23 | Bio 54, Llc | Devices for bleeding reduction and methods of making and using the same |
| TWI803177B (zh) * | 2021-02-05 | 2023-05-21 | 大陸商賽諾哈勃藥業（成都）有限公司 | 一種纖維蛋白溶酶抑制劑、其製備方法及應用 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CN117500799A (zh) | 2021-06-09 | 2024-02-02 | 伊莱利利公司 | 作为kras g12d抑制剂的取代的稠合吖嗪 |
| US11642324B1 (en) | 2022-03-01 | 2023-05-09 | Bio 54, Llc | Topical tranexamic acid compositions and methods of use thereof |
| AU2023251136A1 (en) | 2022-04-05 | 2024-10-17 | Bayer Aktiengesellschaft | Inhibitors of chymase for use in the selective resolution of thrombi in thrombotic or thromboembolic disorders |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2192559A5 (en) * | 1972-07-17 | 1974-02-08 | Ugine Kuhlmann | Pyrimidino (1,2-b) indazole derivs - inters for dyes and pharmaceuticals, from 3-aminoindazoles and beta-ketone derivs |
| WO2006023001A1 (fr) | 2004-07-30 | 2006-03-02 | Xanodyne Pharmaceuticals, Inc. | Formules d’acide tranéxamique |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| KR101673886B1 (ko) * | 2008-06-06 | 2016-11-08 | 사노피 | ＴＡＦＩａ의 억제제로서의 마크로사이클릭 우레아 및 술파미드 유도체 |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CN102459246B (zh) | 2009-04-07 | 2014-05-07 | 阿斯利康(瑞典)有限公司 | 作为治疗剂的异噁唑-3(2h)-酮类似物 |
| WO2012047156A1 (fr) * | 2010-10-04 | 2012-04-12 | Astrazeneca Ab | Analogues d'isoxazol-3(2h)-one comme inhibiteurs du plasminogène et leur utilisation dans traitement de maladies liées à la fibrinolyse |
| NZ610315A (en) * | 2010-11-15 | 2015-08-28 | Univ Leuven Kath | Antiviral condensed heterocyclic compounds |
| WO2012082947A1 (fr) * | 2010-12-16 | 2012-06-21 | Irm Llc | Composés et compositions en tant qu'agonistes de tgr5 |
| CN103370321B (zh) * | 2010-12-16 | 2015-07-29 | 拜耳知识产权有限责任公司 | 取代的嘧啶并[1,2-b]吲唑及其作为PI3K/AKT途径的调节剂的用途 |
| UY35809A (es) * | 2013-11-05 | 2015-05-29 | Bayer Pharma AG | (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos |
| WO2016173948A1 (fr) * | 2015-04-30 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Indazolopyrimidinones comme inhibiteurs de la fibrinolyse |
-
2014
- 2014-10-31 UY UY0001035809A patent/UY35809A/es not_active Application Discontinuation
- 2014-11-03 EP EP14793523.3A patent/EP3066100B1/fr active Active
- 2014-11-03 WO PCT/EP2014/073529 patent/WO2015067549A1/fr not_active Ceased
- 2014-11-03 AP AP2016009175A patent/AP2016009175A0/en unknown
- 2014-11-03 EA EA201690935A patent/EA029373B1/ru not_active IP Right Cessation
- 2014-11-03 ES ES14793523T patent/ES2732305T3/es active Active
- 2014-11-03 SG SG11201602133RA patent/SG11201602133RA/en unknown
- 2014-11-03 TW TW103137976A patent/TWI657089B/zh not_active IP Right Cessation
- 2014-11-03 PE PE2016000586A patent/PE20160934A1/es unknown
- 2014-11-03 MX MX2016005969A patent/MX370419B/es active IP Right Grant
- 2014-11-03 MA MA39018A patent/MA39018A1/fr unknown
- 2014-11-03 AU AU2014345771A patent/AU2014345771B2/en not_active Ceased
- 2014-11-03 CR CR20160332A patent/CR20160332A/es unknown
- 2014-11-03 CN CN201480060660.7A patent/CN105683194B/zh not_active Expired - Fee Related
- 2014-11-03 UA UAA201605980A patent/UA117504C2/uk unknown
- 2014-11-03 TN TN2016000161A patent/TN2016000161A1/en unknown
- 2014-11-03 JP JP2016527398A patent/JP6431061B2/ja not_active Expired - Fee Related
- 2014-11-03 CA CA2929378A patent/CA2929378C/fr not_active Expired - Fee Related
- 2014-11-03 CU CU2016000062A patent/CU24361B1/es unknown
- 2014-11-03 KR KR1020167014622A patent/KR102312780B1/ko not_active Expired - Fee Related
- 2014-11-04 AR ARP140104130A patent/AR098292A1/es not_active Application Discontinuation
- 2014-11-05 US US14/533,915 patent/US9598417B2/en not_active Expired - Fee Related
-
2016
- 2016-03-17 IL IL244645A patent/IL244645B/en active IP Right Grant
- 2016-04-06 ZA ZA2016/02311A patent/ZA201602311B/en unknown
- 2016-05-04 PH PH12016500828A patent/PH12016500828A1/en unknown
- 2016-05-05 GT GT201600084A patent/GT201600084A/es unknown
- 2016-05-05 DO DO2016000102A patent/DOP2016000102A/es unknown
- 2016-05-05 CL CL2016001076A patent/CL2016001076A1/es unknown
-
2017
- 2017-01-26 US US15/416,651 patent/US10098883B2/en active Active
-
2018
- 2018-08-10 US US16/101,250 patent/US10668071B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA39018A1 (fr) | (aza)pyridopyrazolopyrimidinones et indazolopyrimidinones utilisées comme inhibiteurs de la fibrinolyse | |
| SA521421205B1 (ar) | مشتقات 6-(4-أمينو-3-أوكسا-8-ازاسبيرو[4.5]ديكان-8-يل)-3-(2.3-داي كلورو فينيل)-2-ميثيل بيريميدين-4(3h)-اون والمركبات ذات الصلة مثل مثبطات ptpn11 (shp2) لعلاج السرطان | |
| MA39219A1 (fr) | Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique | |
| MA50391B1 (fr) | Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires | |
| MA41179A (fr) | Composés inhibiteurs de parg | |
| MA42376A (fr) | Dérivés d'oxopyridine substitués | |
| EP2091328A4 (fr) | Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d'alzheimer | |
| MA47447B1 (fr) | 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer | |
| MA41134A (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| EP1651623A4 (fr) | Hexahydrodiazepinones utilises en tant qu'inhibiteurs de la dipeptidyl peptidase iv pour le traitement ou la prevention du diabete | |
| MA35826B1 (fr) | Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk | |
| MA33448B1 (fr) | 5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl-carboxamides utilises en tant qu'inhibiteurs de jak | |
| MA47356A1 (fr) | Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases | |
| MA34083B1 (fr) | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques | |
| MA34331B1 (fr) | Composés pyrazole comme inhibiteurs du récepteur sigma | |
| ZA202203520B (en) | [1,4]oxazepino[2,3-c]quinolinone derivatives as bcl6 inhibitors | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| MA38284B1 (fr) | Inhibiteurs de la phospholipase associée aux lipoprotéines a2 (lp-pla2) à base de 2,3-dihydro-imidazol[1,2-c]pyrimidin-5(1 h)-one | |
| MA44948A1 (fr) | Inhibiteurs de bace 1 | |
| EA201590820A1 (ru) | Производные 4-карбоксамидоизоиндолинона в качестве селективных ингибиторов parp-1 | |
| MA38349A1 (fr) | Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3) | |
| EA202191955A1 (ru) | Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| CR20230177A (es) | Compuestos y composiciones como moduladores de señalización tlr | |
| MA37763B1 (fr) | Difluoro-hexahydro-cyclopentaoxazinyles et difluoro-hexahydro-benzooxazinyles en tant qu'inhibiteurs de bace1 |